A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT05651932

Public ClinicalTrials.gov record NCT05651932. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

Study identification

NCT ID: NCT05651932
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: K36 Therapeutics, Inc.; Industry
Enrollment: 165 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 22, 2023 (Actual)
Primary completion: Dec 31, 2027 (Estimated)
Completion: Jun 30, 2028 (Estimated)
Last update posted: Oct 22, 2026

2023 – 2028

United States locations

U.S. sites: 19
U.S. states: 15
U.S. cities: 18

Facility	City	State	ZIP	Site status
UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic	San Francisco	California	94143	Recruiting
Mayo Clinic Hospital - Florida	Jacksonville	Florida	32224	Recruiting
University of Miami Don Soffer Clinical Research Center	Miami	Florida	33136	Not yet recruiting
The Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
University of Michigan	Ann Arbor	Michigan	48109	Not yet recruiting
Mayo Clinic - Transplant Center - Rochester	Rochester	Minnesota	55905	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
Memorial Sloan-Kettering Cancer Center	New York	New York	10065	Recruiting
Atrium Health, Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
Duke University Hospital	Durham	North Carolina	27705	Recruiting
Cleveland Clinic - Taussig Cancer Institute	Cleveland	Ohio	44195	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
Medical University of South Carolina (MUSC) - Hollings Cancer Center	Charleston	South Carolina	29425	Recruiting
Tennessee Oncology	Nashville	Tennessee	37203	Recruiting
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center	Dallas	Texas	75235	Recruiting
Oncology Consultants	Houston	Texas	77030	Recruiting
Northwest Medical Specialties, PLLC	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05651932, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 22, 2026 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05651932 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →